CAP 7.1

Drug Profile

CAP 7.1

Alternative Names: CAP7.1; Etoposide prodrug (CAP7.1) - CellAct Pharma

Latest Information Update: 10 Jun 2016

Price : $50

At a glance

  • Originator CellAct Pharma
  • Class Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Biliary cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Biliary cancer; Non-small cell lung cancer; Small cell lung cancer

Most Recent Events

  • 03 Jun 2016 Population pharmacokinetics data from phase I and phase II trials in Biliary cancer presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2016)
  • 25 Jan 2016 Interim efficacy and adverse events data from the phase II CAP7-1 trial in Biliary cancer, Non-small cell lung cancer and Small cell lung cancer, and interim efficacy data from phase I trial in Biliary cancer and Non-small cell lung cancer released by CellAct Pharma
  • 04 Sep 2015 Phase-II development is ongoing for Solid tumours (biliary, non-small cell lung and small cell lung cancers) in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top